MRC Centre for Global Infectious Disease Analysis, Abdul Latif Jameel Institute for Disease and Emergency Analytics (J-IDEA), School of Public Health, Imperial College London, London, UK.
London School of Hygiene & Tropical Medicine.
Lancet. 2021 Jan 30;397(10272):398-408. doi: 10.1016/S0140-6736(20)32657-X.
The past two decades have seen expansion of childhood vaccination programmes in low-income and middle-income countries (LMICs). We quantify the health impact of these programmes by estimating the deaths and disability-adjusted life-years (DALYs) averted by vaccination against ten pathogens in 98 LMICs between 2000 and 2030.
16 independent research groups provided model-based disease burden estimates under a range of vaccination coverage scenarios for ten pathogens: hepatitis B virus, Haemophilus influenzae type B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, Streptococcus pneumoniae, rotavirus, rubella, and yellow fever. Using standardised demographic data and vaccine coverage, the impact of vaccination programmes was determined by comparing model estimates from a no-vaccination counterfactual scenario with those from a reported and projected vaccination scenario. We present deaths and DALYs averted between 2000 and 2030 by calendar year and by annual birth cohort.
We estimate that vaccination of the ten selected pathogens will have averted 69 million (95% credible interval 52-88) deaths between 2000 and 2030, of which 37 million (30-48) were averted between 2000 and 2019. From 2000 to 2019, this represents a 45% (36-58) reduction in deaths compared with the counterfactual scenario of no vaccination. Most of this impact is concentrated in a reduction in mortality among children younger than 5 years (57% reduction [52-66]), most notably from measles. Over the lifetime of birth cohorts born between 2000 and 2030, we predict that 120 million (93-150) deaths will be averted by vaccination, of which 58 million (39-76) are due to measles vaccination and 38 million (25-52) are due to hepatitis B vaccination. We estimate that increases in vaccine coverage and introductions of additional vaccines will result in a 72% (59-81) reduction in lifetime mortality in the 2019 birth cohort.
Increases in vaccine coverage and the introduction of new vaccines into LMICs have had a major impact in reducing mortality. These public health gains are predicted to increase in coming decades if progress in increasing coverage is sustained.
Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation.
在过去的二十年中,低收入和中等收入国家(LMICs)的儿童疫苗接种计划有所扩大。我们通过估计 2000 年至 2030 年间,98 个 LMIC 中针对十种病原体的疫苗接种预防的死亡人数和伤残调整生命年(DALYs),来量化这些计划的健康影响。
16 个独立的研究小组根据十种病原体的一系列疫苗接种覆盖率情景,提供了基于模型的疾病负担估计:乙型肝炎病毒、乙型流感嗜血杆菌、人乳头瘤病毒、日本脑炎、麻疹、脑膜炎奈瑟菌 A 群、肺炎链球菌、轮状病毒、风疹和黄热病。使用标准化的人口统计数据和疫苗接种覆盖率,通过将无疫苗接种反事实情景与报告和预测的疫苗接种情景下的模型估计进行比较,确定疫苗接种计划的影响。我们按日历年度和年度出生队列展示了 2000 年至 2030 年期间预防的死亡人数和 DALYs。
我们估计,针对十种选定病原体的疫苗接种将预防 2000 年至 2030 年间 6900 万人(95%可信区间 52-88)的死亡,其中 3700 万人(30-48)的死亡发生在 2000 年至 2019 年期间。与无疫苗接种的反事实情景相比,这代表 2000 年至 2019 年期间死亡人数减少了 45%(36-58)。这一影响主要集中在五岁以下儿童死亡率的降低(57%的降低[52-66]),尤其是麻疹。在 2000 年至 2030 年期间出生的出生队列的一生中,我们预测疫苗接种将预防 1.2 亿人(93-150)死亡,其中 5800 万人(39-76)归因于麻疹疫苗接种,3800 万人(25-52)归因于乙型肝炎疫苗接种。我们估计,疫苗覆盖率的提高和新疫苗的引入将使 2019 年出生队列的终生死亡率降低 72%(59-81)。
疫苗接种覆盖率的提高和新疫苗在 LMICs 的引入对降低死亡率产生了重大影响。如果覆盖范围的扩大得到持续,这些公共卫生收益预计将在未来几十年内增加。
全球疫苗免疫联盟(Gavi)、疫苗和免疫全球联盟(The Vaccine Alliance)以及比尔及梅琳达·盖茨基金会。